{"product_id":"srpt-vrio-analysis","title":"Sarepta Therapeutics, Inc. (SRPT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Sarepta Therapeutics, Inc. (SRPT) truly positioned for sustainable success? Our rigorous VRIO analysis cuts straight to the core, examining whether its resources are Valuable, Rare, Inimitable, and Organized to capture a lasting competitive edge. Discover the definitive verdict on Sarepta Therapeutics, Inc. (SRPT)'s strategic strengths and weaknesses immediately below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSarepta Therapeutics, Inc. (SRPT) - VRIO Analysis: 1. ELEVIDYS Gene Therapy Asset (DMD)\u003c\/h2\u003e\u003cp\u003eThis is their flagship asset, the gene therapy for Duchenne muscular dystrophy (DMD), which generated \u003cstrong\u003e$131.5 million\u003c\/strong\u003e in net product revenue in Q3 2025 alone, despite safety headwinds.\u003c\/p\u003e\n\u003cp\u003eYou're looking at the core value driver for Sarepta Therapeutics, Inc. (SRPT), the gene therapy ELEVIDYS. It's a first-in-class treatment that brought in \u003cstrong\u003e$131.5 million\u003c\/strong\u003e in net product revenue in the third quarter of 2025, contributing to total net product sales of \u003cstrong\u003e$370.0 million\u003c\/strong\u003e for the quarter. That revenue stream is huge, but the recent label update in November 2025, adding a boxed warning for acute liver risks, shows the tightrope walk this asset requires.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on its current standing:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment for ELEVIDYS\u003c\/td\u003e\n\u003ctd\u003eKey Data Point (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eNet Product Revenue: \u003cstrong\u003e$131.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eCurrently Rare\u003c\/td\u003e\n\u003ctd\u003eOne of the few approved, commercially available DMD gene therapies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh Cost\/Time\u003c\/td\u003e\n\u003ctd\u003eSpecific viral vector and complex manufacturing process are hard to copy quickly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eStrained\/Adapting\u003c\/td\u003e\n\u003ctd\u003eRecent label changes and prior shipment pauses show operational stress in risk management.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eFirst-mover status is strong, but ongoing safety scrutiny creates near-term vulnerability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Provides a potentially curative treatment for a large segment of the DMD population, driving significant revenue growth.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value proposition is clear: it treats a devastating, progressive disease. The \u003cstrong\u003e$131.5 million\u003c\/strong\u003e in Q3 2025 revenue confirms market demand, even with access issues. Still, the value is contingent on expanding beyond ambulatory patients, which is the focus of the new ENDEAVOR Cohort 8 trial announced in late November 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: As an approved, commercially available gene therapy for DMD, it is currently rare, though competition is emerging.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRight now, being the only approved option for this specific patient group makes it rare. But in biotech, rarity is fleeting. You need to watch for pipeline candidates from other firms aiming at the same target population. That said, having the established regulatory footprint is a major, rare asset in itself.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High. The specific vector, manufacturing process, and regulatory approval pathway are difficult and time-consuming to replicate.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReplicating a successful gene therapy isn't like copying a software feature. It involves proprietary manufacturing know-how and navigating the specific FDA pathway that Sarepta Therapeutics, Inc. has already cleared. That institutional knowledge and established supply chain are defintely hard barriers to entry.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVector design is proprietary.\u003c\/li\u003e\n\u003cli\u003eManufacturing scale-up is complex.\u003c\/li\u003e\n\u003cli\u003eRegulatory precedent is established.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Moderate. The company is organized to commercialize it, but recent safety labeling and shipment pauses show organizational strain in risk mitigation.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is built around commercializing this asset, but the operational hiccups tell a story. Suspending shipments to non-ambulatory patients in June 2025, and then the November 2025 label update adding a boxed warning for liver risks, suggests the commercial and medical affairs teams are constantly reacting to safety signals. They need to streamline risk communication fast.\u003c\/p\u003e\n\u003cp\u003eThe company is actively trying to shore up its foundation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRefinancing of 2027 Notes completed.\u003c\/li\u003e\n\u003cli\u003eCost restructuring initiatives underway.\u003c\/li\u003e\n\u003cli\u003eCash position stood at \u003cstrong\u003e$865.2 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. The first-mover advantage is strong, but the ongoing safety scrutiny and the need for a path to non-ambulatory patients create near-term vulnerability.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is temporary because the market is dynamic. The immediate action is converting the accelerated approval to traditional approval, which they plan to discuss with the FDA in Q1 2026. If they can’t manage the safety profile - like the new liver warning - or expand the label effectively, competitors gaining ground on a cleaner profile will erode this advantage quickly. The clock is ticking on this first-mover lead.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSarepta Therapeutics, Inc. (SRPT) - VRIO Analysis: 2. Exon-Skipping PMO Franchise (DMD)\u003c\/h2\u003e\u003cp\u003eThis established portfolio, including EXONDYS 51, VYONDYS 53, and AMONDYS 45, brought in \u003cstrong\u003e$238.5 million\u003c\/strong\u003e in Q3 2025, showing resilience even with the newer gene therapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a stable, multi-product revenue base, funding pipeline development. The franchise generated \u003cstrong\u003e$967.2 million\u003c\/strong\u003e in net product revenue for the full year 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Other companies have exon-skipping technology, but Sarepta’s specific combination of three FDA-approved products (EXONDYS 51, VYONDYS 53, and AMONDYS 45) is unique in its current market penetration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The specific proprietary PMO chemistry and established patient base are hard to copy quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High, historically, due to successful management and commercialization. However, recent events introduce organizational complexity and risk. The company completed the ESSENCE confirmatory trial commitment for AMONDYS 45 and VYONDYS 53.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, but under pressure. This cash cow historically provided the financial runway to weather R\u0026amp;D volatility.\u003c\/p\u003e\n\n\u003ch3\u003eKey Financial Metrics for Context\u003c\/h3\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePMO Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$238.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePMO Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$967.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$370.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$399.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganizational\/Regulatory Context (ESSENCE Trial)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe ESSENCE study evaluated AMONDYS 45 and VYONDYS 53 compared to placebo.\u003c\/li\u003e\n\u003cli\u003eThe study \u003cstrong\u003efailed to achieve statistical significance\u003c\/strong\u003e on its primary endpoint.\u003c\/li\u003e\n\u003cli\u003eThe p-value reported for the primary endpoint was \u003cstrong\u003eP=0.309\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eManagement is relying on a post-hoc subgroup analysis (excluding COVID-impacted data) and real-world evidence to secure traditional approval.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSarepta Therapeutics, Inc. (SRPT) - VRIO Analysis: 3. Next-Generation siRNA Platform\u003c\/h2\u003e\u003cp\u003eThis platform is the focus for future growth, with data readouts expected later in 2025 for DM1 and FSHD1 programs, complementing their DMD leadership.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe platform diversifies the company beyond Duchenne Muscular Dystrophy (DMD) into chronic treatment modalities for other rare diseases. The agreement with Arrowhead Pharmaceuticals grants exclusive global rights to multiple clinical and preclinical programs, including those for Myotonic Dystrophy Type 1 (DM1) and Facioscapulohumeral Muscular Dystrophy (FSHD).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset (Internal Code)\u003c\/td\u003e\n\u003ctd\u003eIndication\u003c\/td\u003e\n\u003ctd\u003ePartner Payment Triggered\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRP-1003 (ARO-DM1)\u003c\/td\u003e\n\u003ctd\u003eMyotonic Dystrophy Type 1 (DM1)\u003c\/td\u003e\n\u003ctd\u003e$100.0 million milestone in July 2025; additional $200 million milestone triggered\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRP-1001 (ARO-DUX4)\u003c\/td\u003e\n\u003ctd\u003eFacioscapulohumeral Muscular Dystrophy (FSHD)\u003c\/td\u003e\n\u003ctd\u003eClinical-stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRP-1002 (ARO-MMP7)\u003c\/td\u003e\n\u003ctd\u003eIdiopathic Pulmonary Fibrosis (IPF)\u003c\/td\u003e\n\u003ctd\u003eClinical-stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRP-1004 (ARO-ATXN2)\u003c\/td\u003e\n\u003ctd\u003eSpinocerebellar Ataxia 2 (SCA2)\u003c\/td\u003e\n\u003ctd\u003eClinical-stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe specific combination of clinical-stage assets utilizing Arrowhead's Targeted RNAi Molecule (TRiM) platform provides a near-term, unique asset mix complementing Sarepta's existing portfolio. The initial deal involved a significant capital deployment to secure these rights.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Cash Payment to Arrowhead\u003c\/td\u003e\n\u003ctd\u003e$500 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity Investment in Arrowhead Stock\u003c\/td\u003e\n\u003ctd\u003e$325 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Initial Cash\/Equity Outlay\u003c\/td\u003e\n\u003ctd\u003e$825 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eSarepta has secured exclusive global rights to the key clinical-stage programs, creating a barrier to direct imitation for those specific assets. Competitors face the challenge of replicating the secured intellectual property rights.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe July 16, 2025, strategic restructuring explicitly prioritized the siRNA platform for long-term growth, following preliminary Q2 2025 net product revenue of $513 million. The company held approximately $850 million in cash and investments as of June 30, 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWorkforce reduction: 36% of approximately 500 employees.\u003c\/li\u003e\n\u003cli\u003eAnticipated annual cost savings (starting 2026): Approximately $400 million.\u003c\/li\u003e\n\u003cli\u003eCost savings from pipeline reprioritization: Approximately $300 million annually.\u003c\/li\u003e\n\u003cli\u003eCost savings expected by end of 2025: Over $100 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe advantage is temporary, contingent on achieving proof of biology first. Data readouts for the DM1 and FSHD1 programs are expected later in 2025. Success in these readouts is positioned to convert the temporary advantage into a sustained one.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSarepta Therapeutics, Inc. (SRPT) - VRIO Analysis: 4. AAVrh.74 Vector Expertise\u003c\/h2\u003e\u003cp\u003eThis is the specific adeno-associated virus vector used in ELEVIDYS and the LGMD candidate SRP-9003. Experience here is deep, despite recent safety concerns.\u003c\/p\u003e\n\n\u003cp\u003eThe expertise surrounding the rAAVrh74 viral vector is central to Sarepta's gene therapy franchise, underpinning both the approved therapy ELEVIDYS and the late-stage LGMD candidate SRP-9003.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Essential proprietary knowledge for delivering gene therapies to muscle tissue, a core competency for their DMD\/LGMD franchise. The FDA granted platform technology designation to the rAAVrh74 viral vector used in SRP-9003, recognizing its reproducibility and adaptability across multiple therapeutic programs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. The specific, proven experience in scaling and manufacturing this vector for systemic use in these indications is rare. In DMD patients treated with ELEVIDYS, about 86% did not have pre-existing antibodies against rAAVrh74, suggesting its utility over other AAV serotypes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Manufacturing and regulatory navigation around a specific AAV vector is a multi-year, high-cost barrier. Platform-driven AAV manufacturing development can take months or even years off development timelines and lower bespoke development costs. The broader Viral Vector Manufacturing Market is projected to reach \\$1.85B to \\$4.46B by 2030. Sarepta employs a hybrid model, controlling differentiated aspects internally while leveraging dedicated capacity with partners like Catalent.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. While the expertise exists, recent patient deaths tied to the platform (though not exclusively linked to SRP-9003) raise questions about the organization’s ability to manage the associated risk profile. The recommended dose for ELEVIDYS is $1.33 \\times 10{14}$ vector genomes (vg) per kg for patients weighing less than 70 kg.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The institutional knowledge around this specific vector is a significant moat, provided safety hurdles are cleared. The platform designation supports leveraging previous data to speed up testing and approval for new treatments using rAAVrh74.\u003c\/p\u003e\n\u003cp\u003eThe clinical validation of the AAVrh.74 vector in the SRP-9003 Phase III EMERGENE trial for LGMD2E\/R4 provides concrete data on its functional delivery capability:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (SRP-9003, Day 60)\u003c\/th\u003e\n\u003cth\u003eAmbulatory Patients (N=11)\u003c\/th\u003e\n\u003cth\u003eNon-Ambulatory Patients (N=6)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMean $\\beta$-SG Expression Change from Baseline (PPF)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMean $\\beta$-SG Expression Change from Baseline (PFI)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.23%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21.81%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients with Treatment-Related Acute Liver Injury (TEAEs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7$ patients ($\\approx 41.2\\%$)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe successful transduction and expression data reinforce the vector's utility, which is further supported by the following organizational capabilities:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe vector is designed to robustly transduce skeletal, diaphragm, and cardiac muscle.\u003c\/li\u003e\n\u003cli\u003eThe MHCK7 promoter is utilized with SRP-9003 for robust expression in the heart.\u003c\/li\u003e\n\u003cli\u003eSarepta's internal competencies span process development, analytical development, quality control, and pre-clinical manufacturing.\u003c\/li\u003e\n\u003cli\u003eThe company's goal is to build the largest gene therapy manufacturing capacity in the industry via its hybrid model.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSarepta Therapeutics, Inc. (SRPT) - VRIO Analysis: 5. Rare Disease Patient Access Infrastructure\u003c\/h2\u003e\u003cp\u003eThe ability to identify, enroll, and treat patients with ultra-rare conditions like DMD and LGMD across the US.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly translates approved therapies into revenue by ensuring eligible patients can receive treatment, even with complex logistics like infusions.\u003c\/p\u003e\n\u003cp\u003eThe translation of approved therapies into revenue is evidenced by significant net product revenue growth:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$359.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Product Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e55%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eELEVIDYS Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$133.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRNA-based PMOs Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$225.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Product Revenue (Preliminary)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.79 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eELEVIDYS Net Product Revenue (Preliminary)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$820.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Total Net Product Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 to $3.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Other rare disease companies have access, but Sarepta’s focus on neuromuscular diseases is specialized.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Building the specialized treatment center network and physician relationships takes time and trust.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company is focused on patient-centric delivery, though administrative hurdles have caused temporary slowdowns.\u003c\/p\u003e\n\u003cp\u003eProgress in expanding patient access to new modalities demonstrates organizational focus:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnrollment and dosing complete in EMERGENE (Phase 3 for SRP-9003 for LGMD2E\/R4) as of December 2024.\u003c\/li\u003e\n\u003cli\u003eSarepta remains on track to submit a Biologics License Application (BLA) to the U.S. FDA for SRP-9003 in the second half of \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe U.S. Food and Drug Administration (FDA) approved ELEVIDYS for non-ambulatory patients on June 22, \u003cstrong\u003e2023\u003c\/strong\u003e, under the accelerated approval pathway.\u003c\/li\u003e\n\u003cli\u003eELEVIDYS received traditional approval for ambulatory DMD patients 4 years of age and older on June 20, \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Deep, established relationships in a niche patient community are hard to displace.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSarepta Therapeutics, Inc. (SRPT) - VRIO Analysis: 6. Intellectual Property on Exon-Skipping\u003c\/h2\u003e\u003cp\u003eThe foundational patents covering the use of antisense oligonucleotides (PMOs) to skip specific exons in the DMD gene.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePMO Drug\u003c\/td\u003e\n\u003ctd\u003eNet Product Revenue (Q1 2024)\u003c\/td\u003e\n\u003ctd\u003eNet Product Revenue (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXONDYS 51\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$120.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncluded in total PMO revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMONDYS 45\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$71.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncluded in total PMO revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVYONDYS 53\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncluded in total PMO revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eProtects revenue stream from PMO drugs: Q1 2024 PMO franchise net product revenue was \u003cstrong\u003e$225.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eQ3 2024 PMO net product revenue was approximately \u003cstrong\u003e$248.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSpecific composition-of-matter and method-of-use patents are proprietary.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003ePatent thickets are complex and expensive to navigate or challenge legally.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eActive maintenance and protection of the portfolio.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003ePatent protection extends through at least \u003cstrong\u003e2038\u003c\/strong\u003e for some patents, excluding extensions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSarepta Therapeutics, Inc. (SRPT) - VRIO Analysis: 7. Strategic Partnership with Roche\u003c\/h2\u003e\u003cp\u003eThe collaboration agreement provides contract manufacturing revenue and royalty streams from Roche’s sales of ELEVIDYS outside the US.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Provides non-US commercial reach and a reliable, lower-risk revenue component, as seen by the Q1 2025 royalty revenue of \u003cstrong\u003e$4.0 million\u003c\/strong\u003e. This revenue stream is supplemented by contract manufacturing fees for supplying Roche with commercial batches of ELEVIDYS for ex-US sales.\u003c\/p\u003e\n\u003cp\u003eThe financial contributions from the Roche agreement for recent periods include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCollaboration and other revenues recognized for the three months ended June 30, 2025, totaled \u003cstrong\u003e$98.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eContract manufacturing revenue recognized for the three months ended June 30, 2025, was \u003cstrong\u003e$27.0 million\u003c\/strong\u003e, related to commercial ELEVIDYS supply shipments to Roche.\u003c\/li\u003e\n\u003cli\u003eFor the three months ended March 31, 2025, royalty revenue from Roche's sales of ELEVIDYS was \u003cstrong\u003e$4.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCollaboration revenues recognized in Q1 2025 also included \u003cstrong\u003e$112.0 million\u003c\/strong\u003e related to the expiration of a Roche option for an external Duchenne development program.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe scale of Roche's ex-US sales activity, which underpins the royalty stream, reached 137 million Swiss francs (approximately \u003cstrong\u003e$156 million\u003c\/strong\u003e) over the first nine months of the year prior to October 2024.\u003c\/p\u003e\n\u003cp\u003eThe progression of key revenue components from the Roche agreement is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod Ended June 30, 2025 (3 Months)\u003c\/th\u003e\n\u003cth\u003ePeriod Ended March 31, 2025 (3 Months)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Manufacturing Revenue (from Roche Supply)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Revenue from Roche Sales\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated for Q2 2025 alone\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Collaboration and Other Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$98.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$133 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Low. Many biotechs have pharma partnerships, but the scope and scale with a major player like Roche for ex-US commercialization of a gene therapy are specific.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: High. Replicating a complex, multi-year global licensing and supply deal with established regulatory and commercial infrastructure like Roche's is not easily done.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High. The company is actively managing the supply chain aspects of this agreement, evidenced by recognizing \u003cstrong\u003e$27.0 million\u003c\/strong\u003e in contract manufacturing revenue in Q2 2025 from supplying commercial batches.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. While valuable now, the advantage depends on the continued success and relationship with Roche in ex-US markets for ELEVIDYS.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSarepta Therapeutics, Inc. (SRPT) - VRIO Analysis: 8. LGMD Pipeline Advancement (SRP-9003)\u003c\/h2\u003e\u003cp\u003eThe BLA submission for SRP-9003 for LGMD type 2E\/R4 is on track for the second half of 2025, potentially leading to the first LGMD approval.\u003c\/p\u003e\n\n\u003cp\u003eData from the Phase 3 EMERGENE study are anticipated in the \u003cstrong\u003efirst half of 2025\u003c\/strong\u003e, with a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration planned for the \u003cstrong\u003esecond half of 2025\u003c\/strong\u003e seeking accelerated approval.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Opens a significant new rare disease market segment, leveraging their gene therapy platform expertise outside of DMD.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Being first-to-market in a specific LGMD subtype is a major differentiator.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. The clinical trial completion and BLA submission represent years of focused, high-risk investment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company has kept this program on track despite other pressures, confirming FDA pathway alignment. Sarepta reported net product revenue of \u003cstrong\u003e$611.5 million\u003c\/strong\u003e for the first quarter of 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eEndpoint\/Cohort\u003c\/th\u003e\n\u003cth\u003eMeasure\u003c\/th\u003e\n\u003cth\u003eAmbulatory Patients (n=11) Mean CFBL (Day 60)\u003c\/th\u003e\n\u003cth\u003eNon-Ambulatory Patients (n=6) Mean CFBL (Day 60)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint (PPF)\u003c\/td\u003e\n\u003ctd\u003e% Positive Fibers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e43.4%\u003c\/strong\u003e [SD: 29.9%] (P \u0026lt; .001)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23.9%\u003c\/strong\u003e [SD: 14.2%] (P \u0026lt; .02)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecondary Endpoint (PFI)\u003c\/td\u003e\n\u003ctd\u003e% Fluorescent Intensity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e18.23%\u003c\/strong\u003e [SD: 11.23%] (P \u0026lt; .001)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21.81%\u003c\/strong\u003e [SD: 14.04%]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExploratory Endpoint (CK)\u003c\/td\u003e\n\u003ctd\u003eSerum Creatine Kinase CFBL\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e−88.8%\u003c\/strong\u003e (SD: 10.9%; Range: −99.6% to −66.8%)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e−92.4%\u003c\/strong\u003e (SD: 4.5%; Range: −97.1% to −86.7%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. If approved, this creates a sustained advantage until competitors catch up in that specific LGMD indication.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe EMERGENE trial design serves as a pathfinder for other LGMD pipeline programs.\u003c\/li\u003e\n\u003cli\u003eThe LGMD2D program (SRP-9004) has completed enrollment and dosing in Study SRP-9004-102 (DISCOVERY).\u003c\/li\u003e\n\u003cli\u003eThe LGMD2C program (SRP-9005) is expected to initiate its first-in-human study (COMPASS) in the \u003cstrong\u003efirst quarter of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSarepta Therapeutics, Inc. (SRPT) - VRIO Analysis: 9. Financial Restructuring and Cost Discipline\u003c\/h2\u003e\u003cp\u003eThe July 2025 restructuring is projected to deliver approximately $400 million in annual cost reductions starting in 2026, strengthening the balance sheet after refinancing debt.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic restructuring announced in July 2025 is projected to reduce non-GAAP R\u0026amp;D and SG\u0026amp;A expenses to between \u003cstrong\u003e$800 million\u003c\/strong\u003e and \u003cstrong\u003e$900 million\u003c\/strong\u003e annually starting in \u003cstrong\u003e2026\u003c\/strong\u003e, down from previous levels. This initiative is designed to position the Company to meet its 2027 financial obligations, which included an aggregate principal value of $1.15 billion on convertible notes due September 15, 2027. As of June 30, 2025, the Company held approximately \u003cstrong\u003e$850 million\u003c\/strong\u003e in cash, cash equivalents, restricted cash and investments, with an additional \u003cstrong\u003e$600 million\u003c\/strong\u003e available via a revolving credit facility. Total long-term debt was recorded at \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e at the end of the second quarter. The Company had negative free cash flow of \u003cstrong\u003e$695 million\u003c\/strong\u003e in the last twelve months preceding the restructuring announcement.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$513.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 (Preliminary)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eELEVIDYS Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$282 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 (Preliminary)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRNA-based PMOs Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$231 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 (Preliminary)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$850 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Long-Term Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of end of Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Refinanced\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$700 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAugust 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe $400 million in anticipated annual cost reductions starting in 2026 is derived from two primary actions: a 36% workforce reduction, impacting approximately 500 employees, projected to yield approximately $120 million in annual cash cost savings, and pipeline reprioritization expected to deliver approximately $300 million in non-personnel cost savings. The Company is on track to realize over $100 million in cost savings through the end of 2025. The debt refinancing involved exchanging approximately $700 million of 1.25% convertible notes due 2027 for $602 million in new 4.875% notes due 2030, along with up to 6.7 million shares of common stock and approximately $123.3 million in cash. Approximately $450 million of the original 2027 notes remain outstanding.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Improves the path to profitability and ensures the company can meet its 2027 debt obligations, providing financial stability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies restructure, but achieving this level of savings while maintaining key commercial operations is notable.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. The specific actions (workforce reduction, pipeline reprioritization) are company-specific decisions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management executed a decisive plan to align expenses with revised revenue guidance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A leaner, more focused cost structure is a durable operational advantage in the volatile biotech sector.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe Company had suspended its fiscal year 2025 product revenue guidance of $2.3-$2.6 billion. The first half of 2025 performance totaled approximately $1.125 billion. Analyst projections following the July 16 restructuring announcement provided scenarios for the remainder of the year; the Base Case Scenario projected Q3 2025 revenue between $350 million and $450 million, and Q4 2025 revenue between $300 million and $400 million. The internal finance directive requires drafting a 13-week cash view incorporating Q3 2025 actuals and projected Q4 2025 revenue by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516257624213,"sku":"srpt-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/srpt-vrio-analysis.png?v=1740213133","url":"https:\/\/dcf-model.com\/fr\/products\/srpt-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}